Capricor Therapeutics (CAPR) EBITDA (2010 - 2026)

Capricor Therapeutics' EBITDA history runs 17 years deep, the most recent figure standing at -$34.5 million for Q1 2026.

• In Q1 2026, EBITDA fell 46.19% year-over-year to -$34.5 million; the TTM figure through Mar 2026 stood at -$116.6 million (down 117.72% YoY), while the FY2025 annual figure was -$105.8 million, down 166.66% from the prior year.
• EBITDA was -$34.5 million for Q1 2026 at Capricor Therapeutics, down from -$30.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$639484.0 in Q4 2023 to a low of -$34.5 million in Q1 2026.
• Historically, EBITDA has averaged -$13.6 million across 5 years, with a median of -$7.8 million in 2022.
• The sharpest annual moves came in 2023 and 2024: EBITDA surged 91.72% in 2023, then sank 865.79% in 2024.
• A 5-year view of EBITDA shows it stood at -$7.7 million in 2022, then soared by 91.72% to -$639484.0 in 2023, then tumbled by 865.79% to -$6.2 million in 2024, then plunged by 397.8% to -$30.7 million in 2025, then declined by 12.22% to -$34.5 million in 2026.
• The last three EBITDA figures came in at -$34.5 million (Q1 2026), -$30.7 million (Q4 2025), and -$25.1 million (Q3 2025), per Business Quant data.